Navidea biopharmaceuticals announces the regulatory approval of lymphoaim in india

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the regulatory approval of lymphoaim (“lymphoseek” in the rest of the world; tc99m tilmanocept) by the central drugs standard control organisation, india. tc99m tilmanocept is approved for imaging and intraoperative detection of sentinel lymph nodes draining a primary
NAVB Ratings Summary
NAVB Quant Ranking